Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 80

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 80
---
 Stock Warrants issued pursuant to this offering. 48 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATI ONS You should read the following discussion of our financial condition and results of operations in conjunction with our financial statements and the notes included elsewhere in this prospectus. The following discussion contains forward -looking statements that involve certain risks and uncertainties. Our actual results could differ materially from those discussed in these statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this proxy statement / prospectus, particularly under the “Risk Factors” and “Disclosure Regarding Forward -Looking Statements” sections. Throughout this section, unless otherwise noted, “we,” “our,” “us,” “Revelation” and the “Company” refer to Revelation Biosciences, Inc. and its subsidiary. Overview Revelation is a clinical -stagelife science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. We are developing a pipeline of potential high -valueproducts based on Gemini. Gemini is our proprietary formulation of PHAD an established TLR4 agonist that can stimulate the human body’s innate immune response to prevent and treat disease. Our current Gemini based programs consist of: GEM -AKI, which is being developed as a potential therapy for the prevention and treatment of acute kidney injury; GEM -CKD, which is being developed as a potential therapy for the prevention and treatment of chronic kidney disease; GEM -PSI, which is being developed for the prevention and treatment of post surgical infection; and GEM -PBIas a prevention of infection in severe burn patients requiring hospitalization. Since our inception, we have devoted substantially all of our resources to organizing and staffing our Company, business planning, raising capital, and research and development of our Product Candidates. We have funded our operations since our inception to December 31, 2024 through the issuance and sale of our capital stock, from which we have raised net proceeds of $56.7 million. Our current cash and cash equivalents balance will not be sufficient to complete all necessary product development or future commercialization efforts. We anticipate that our current cash and cash equivalents balance will not be sufficient to sustain operations within one -yearafter the date that our audited financial statements for December 31, 2024 were issued, which raises substantial doubt about our ability to continue as a going concern. We plan to seek additional funding through public or private equity or debt financings. We may not be